Two years’ long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment
Open Access
- 9 December 2016
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 10 (2) , 91-101
Abstract
Background: Administration of intravenous immunoglobulins (IVIgs) is established for long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Prevention of secondary axonal loss going along with permanent clinical disability and muscular atrophy is a major aim in CIDP therapy. To assess long-term clinical efficacy of IVIg treatment despite heterogenous disease course and variable complaints reported by the patients, long-term electrophysiological monitoring was performed for systematic evaluation of therapeutic efficacy of IVIg. Methods: A total of 21 patients with CIDP treated with IVIg 1 g/kg bodyweight every 3–6 weeks were examined electrophysiologically every 12 months over a period of 2 years. Results: Assessment of clinical symptoms, using the Inflammatory Neuropathy Cause and Treatment (INCAT) and Hughes functional grading score (F-score) revealed improvement of motor and sensory symptoms over a period of 2 years. As electrophysiological results remained stable, IVIg treatment seems to be suitable to prevent axonal loss in CIDP. Conclusions: This study confirms efficacy of IVIg as firstline therapy in CIDP. Doses and frequency of IVIg application should be adapted based on clinical evaluation and analysis of long-term electrophysiological findings.Keywords
This publication has 47 references indexed in Scilit:
- Advances in the diagnosis, pathogenesis and treatment of CIDPNature Reviews Neurology, 2011
- Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathyTherapeutic Advances in Neurological Disorders, 2011
- CIDP – the relevance of recent advances in Schwann cell/axonal neurobiologyJournal of the Peripheral Nervous System, 2011
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First RevisionJournal of the Peripheral Nervous System, 2010
- Incidence and prevalence of CIDP and the association of diabetes mellitusNeurology, 2009
- Long-term effects of intravenous immunoglobulin in CIDPClinical Neurophysiology, 2007
- Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 casesJournal of Neurology, Neurosurgery & Psychiatry, 2006
- High‐dose cyclophosphamide results in long‐term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathyJournal of the Peripheral Nervous System, 2005
- Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissuesClinical Immunology and Immunopathology, 1992